Payment overview · 2025
General Payments
$190.76
10 reported records · 6 companies
Healthcare provider profile · identity verified
David Vu, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · OKLAHOMA CITY, OK · NPI 1851367999
Verified facts
What the public records show
CMS Open Payments records show David Vu, M.D. received $190.76 in general payments during 2025 across 10 reported records.
Pulmonx Corporation accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $53.59 | 28.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.86 | 24.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.82 | 15.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.16 | 15.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.92 | 9.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.41 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $190.76 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $53.59 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $53.59 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $53.59 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $53.59 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.86 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.82 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.82 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1346 | 139 |
| Atorvastatin Calcium | Atorvastatin Calcium | 624 | 174 |
| Amlodipine Besylate | Amlodipine Besylate | 508 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 329 | 85 |
| Losartan Potassium | Losartan Potassium | 321 | 98 |
| Gabapentin | Gabapentin | 291 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 287 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 277 | 74 |
| Prednisone | Prednisone | 266 | 140 |
| Metformin Hcl | Metformin Hcl | 262 | 76 |
| Tizanidine Hcl | Tizanidine Hcl | 256 | 58 |
| Lisinopril | Lisinopril | 241 | 65 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 235 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 66 |
| Ibuprofen | Ibuprofen | 208 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 56 |
| Montelukast Sodium | Montelukast Sodium | 184 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 184 | 23 |
| Simvastatin | Simvastatin | 182 | 48 |
| Alprazolam | Alprazolam | 179 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 178 | 16 |
| Omeprazole | Omeprazole | 167 | 51 |
| Potassium Chloride | Potassium Chloride | 166 | 41 |
| Glipizide Er | Glipizide | 163 | 44 |
| Furosemide | Furosemide | 148 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 42 |
| Lovastatin | Lovastatin | 143 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 43 |
| Meloxicam | Meloxicam | 129 | 39 |
| Azithromycin | Azithromycin | 128 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 128 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 128 | 22 |
| Famotidine | Famotidine | 125 | 40 |
| Ondansetron Odt | Ondansetron | 124 | 26 |
| Pregabalin | Pregabalin | 124 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 44 |
| Carvedilol | Carvedilol | 119 | 39 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 118 | 58 |
| Alendronate Sodium | Alendronate Sodium | 110 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 24 |
| Sertraline Hcl | Sertraline Hcl | 98 | 29 |
| Eliquis | Apixaban | 97 | 23 |
| Diazepam | Diazepam | 95 | 13 |
| Tramadol Hcl | Tramadol Hcl | 94 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 21 |
| Allopurinol | Allopurinol | 91 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 24 |
| Glipizide | Glipizide | 83 | 22 |
| Metformin Hcl Er | Metformin Hcl | 83 | 28 |
| Atenolol | Atenolol | 74 | 20 |
| Promethazine Hcl | Promethazine Hcl | 74 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 68 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 15 |
| Trazodone Hcl | Trazodone Hcl | 60 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 19 |
| Mounjaro | Tirzepatide | 57 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 55 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 15 |
| Finasteride | Finasteride | 54 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 43 |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | 19 |
| Clonidine Hcl | Clonidine Hcl | 47 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 42 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 37 |
| Fluconazole | Fluconazole | 44 | 17 |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Olanzapine | Olanzapine | 41 | 11 |
| Levetiracetam | Levetiracetam | 40 | 11 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | 17 |
| Jardiance | Empagliflozin | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Ozempic | Semaglutide | 34 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 17 |
| Temazepam | Temazepam | 33 | suppressed |
| Estradiol | Estradiol | 31 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Latanoprost | Latanoprost | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 26 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 12 |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 19 | suppressed |
| Klor-Con 10 | Potassium Chloride | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 11 |
| Naproxen | Naproxen | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Ssd | Silver Sulfadiazine | 15 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Risperidone | Risperidone | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $190.76 · 10 records | Pulmonx Corporation | AIRSUPRA, CHARTIS CATHETER, MOUNJARO, OTEZLA, PULMONX CHARTIS TABLET CONSOLE, QULIPTA, REPATHA, VRAYLAR, YUPELRI, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error